beta
Trial Radar AI
Clinical Trial NCT05414396 for Diabetes Mellitus, Obesity-Related Malignant Neoplasm is active, not recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.
One trial matched filter criteria
Card View
Back to Search

Eat, Move, Live Program for the Reduction of Cancer and Chronic Disease Risk in Underserved Communities

Active, not recruiting
Clinical Trial NCT05414396 is an interventional study for Diabetes Mellitus, Obesity-Related Malignant Neoplasm that is active, not recruiting. It started on 20 March 2018 with plans to enroll 347 participants. Led by City of Hope Medical Center, it is expected to complete by 12 October 2026. The latest data from ClinicalTrials.gov was last updated on 5 December 2025.
Brief Summary
This clinical trial tests the Eat, Move, Live (EML) Program in reducing the risk of chronic diseases among underserved communities by improving healthy lifestyle practices, increasing physical activity and encouraging healthy eating behaviors. EML is a series of free culturally and linguistically appropriate nutrition and physical activity sessions. The interactive education segment of the EML Program is culturally responsive, and based on the community EML program, and topics will include: nutrition guidelines, reading food labels, recipe modification and healthy food preparation, eating healthy on a budget, chronic diseases information and prevention strategies. The EML program may help reduce the risk of cancer and chronic diseases by encouraging more physical activity and healthy eating behaviors.
Detailed Description
PRIMARY OBJECTIVES:

I. To evaluate program by assessing in combination with standard of care metformin: Changes in participants' knowledge, attitudes, and behavior.

II. To evaluate program by assessing in combination with standard of care metformin: Changes in body measurements.

III. To evaluate program by assessing in combination with standard of care metformin: Changes in biomarkers.

OUTLINE:

Participants attend EML program sessions weekly for 12 weeks including an educational session chronic disease risk reduction via nutrition and physical activity, a physical activity session, and a cooking/taste test demonstration.

Official Title

Reducing Cancer and Chronic Disease Risk in Underserved Communities: Eat, Move, Live Program

Conditions
Diabetes MellitusObesity-related Malignant Neoplasm
Other Study IDs
NCT ID Number
NCT05414396
Start Date (Actual)
2018-03-20
Last Update Posted
2025-12-05
Completion Date (Estimated)
2026-10-12
Enrollment (Estimated)
347
Study Type
Interventional
PHASE
N/A
Status
Active, not recruiting
Primary Purpose
Supportive Care
Design Allocation
N/A
Interventional Model
Single Group
Masking
None (Open Label)
Arms / Interventions
Participant Group/ArmIntervention/Treatment
ExperimentalSupportive care (EML program)
Participants attend EML program sessions weekly for 12 weeks including an educational session chronic disease risk reduction via nutrition and physical activity, a physical activity session, and a cooking/taste test demonstration.
Behavioral Intervention
Attend EML program sessions
Questionnaire Administration
Ancillary studies
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Changes in attitudes and beliefs as measured by questionnaires from baseline to week 12
Attitudes and beliefs regarding causes of diabetes asked in questionnaire, measured by endorsing one of the Likert-type scale values ranging from 1 (Agree) to 7 (Disagree).
Baseline and week 12
Changes in behavior as measured by questionnaires from baseline to week 12
Behaviors related to food consumption asked in questionnaires, measured by endorsing one of "None", "1", "2-3", "4-6", "7 or more".
Baseline and week 12
Changes in height from baseline to week 12
Height measured in meters
Baseline to 12 weeks
Changes in weight from baseline to week 12
Weight measured in Kilograms
Baseline to 12 weeks
Changes in waist circumference from baseline to week 12
Hip circumference measured in centimeters
Baseline to 12 weeks
Changes in chest circumference from baseline to week 12
Chest circumference measured in centimeters
Baseline to 12 weeks
Changes in right upper arm circumference from baseline to week 12
Right upper arm circumference measured in centimeters
Baseline to 12 weeks
Changes in left upper arm circumference from baseline to week 12
Left upper arm circumference measured in centimeters
Baseline to 12 weeks
Changes in right upper thigh circumference from baseline to week 12
Right upper thigh circumference measured in centimeters
Baseline to 12 weeks
Changes in left upper thigh circumference from baseline to week 12
Left upper thigh circumference measured in centimeters
Baseline to 12 weeks
Changes in body fat percentage from baseline to week 12
Body fat percentage measured in percent using a handheld BMI machine that calculates body fat percentage.
Baseline to 12 weeks
Changes in systolic blood pressure from baseline to week 12
Systolic blood pressure measured in mmHG
Baseline to 12 weeks
Changes in diastolic blood pressure from baseline to week 12
Diastolic blood pressure measured in mmHG
Baseline to 12 weeks
Changes in hip circumference from baseline to week 12
Hip circumference measured in centimeters
Baseline to 12 weeks
Changes in biomarkers
Will be collected at baseline and follow up based on glycosylated hemoglobin (A1C) measuring guidelines.
Baseline to 12 weeks
Eligibility Criteria

Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
Accepts Healthy Volunteers
Yes
  • Agrees to group consent at week 1
  • Age over 18
  • Able to speak and understand English and/or Spanish

  • Don't agree to group consent at week 1
  • Age younger than 18
  • Not able to speak and understand English and/or Spanish
  • Can't participate in physical activity
City of Hope Medical Center logoCity of Hope Medical Center344 active trials to explore
National Cancer Institute (NCI) logoNational Cancer Institute (NCI)3028 active trials to explore
No contact data.
1 Study Locations in 1 Countries

California

City of Hope Medical Center, Duarte, California, 91010, United States